Rome, Italy | info@neomatrixbiotech.com |
Personalizing cancer Immunotherapy with our DNA

Where we are

Preclinical studies completed

Biomarker assay under advanced development

Specialty Oncology Centers / KOLs identified and ready to start

Cancer Targets

Melanoma

Lung Cancer

Brands and Partners

Our Partners

 
Reference
Aurisicchio L, Pallocca M, Ciliberto G, Palombo F.
J Exp Clin Cancer Res. 2018 Apr 20;37(1):86. doi: 10.1186/s13046-018-0751-1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958

 


© 2023 NEOMATRIX SRL | P. IVA 15698291000 | ALL RIGHTS RESERVED